Skip to content

Continuous Glucose Monitors for Children With Diabetes Mellitus

DirecNet Inpatient Study to Test the Accuracy of Continuous Blood Glucose Monitoring Devices in Children With Type 1 Diabetes

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00069537
Enrollment
90
Registered
2003-09-30
Start date
2002-05-31
Completion date
2002-11-30
Last updated
2016-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Insulin-Dependent

Keywords

Diabetes Mellitus, Insulin-Dependent, Type 1 Diabetes, Diabetes in Children, Continuous Glucose Monitoring Devices

Brief summary

Good control of blood glucose levels is important in preventing complications from diabetes. This study assessed the accuracy and reliability of two FDA-approved continuous glucose monitors, the Continuous Glucose Monitoring System (CGMS) and the GlucoWatch G2 Biographer (GW2B), in children with type 1 diabetes mellitus (T1DM).

Detailed description

Intensive control of blood glucose levels has been shown to substantially prevent or delay complications of T1DM in adolescents and adults. The major limitation to implementation of intensive glycemic control is hypoglycemia. Younger children may be at increased risk for hypoglycemia and the risk/benefit ratio of intensive glycemic control may be less favorable in this population. Intensive therapy has not been systematically evaluated in children less than 13 years of age. This study was conducted by the Diabetes Research in Children Network (DirecNet) to assess the accuracy of the CGMS and the GW2B glucose monitors in comparison with standard blood glucose measurements in an inpatient setting. During 24-hour clinical research center stays at five clinical centers, approximately 90 children and adolescents with T1DM (1 to 17 years of age) wore two FDA-approved continuous glucose monitors, CGMS and GW2B, and had frequent serum glucose determinations during the day and night. To assess glucose monitor function during periods of rising and falling blood glucose, insulin-induced hypoglycemia and meal-induced hyperglycemia tests were also performed.

Interventions

DEVICEThe GlucoWatch® G2™ Biographer (GW2B)
DEVICEThe Continuous Glucose Monitoring System (CGMS™)

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Jaeb Center for Health Research
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of type 1 diabetes mellitus for at least 1 year prior to study entry * For children over 2 years of age, body mass index between the 5th and 95th percentile for age and gender * Weight \>= 12 kg (26.5 lbs) if \< 7 years of age and \>= 16 kg (35 lbs) if \>7 years of age * Normal hematocrit

Exclusion criteria

* Current use of glucocorticoids * Skin or other medical disorders that would affect completion of the study * History of seizures other than those attributable to either hypoglycemia or high fever

Design outcomes

Primary

MeasureTime frame
Accuracy of the GlucoWatch G2 Biographer and CGMS

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026